Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Product Code | BJAb; BJA-B; BJAB-1; BJA-B1; BJA-B-1 |
| Species | Human |
| Cat.No | ABC-TC514S |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Peripheral Blood |
| Disease | Burkitt’s Lymphoma |
| Storage | Liquid Nitrogen |
| Product Type | Human Lymphoma Cell Lines |
BJAB cells, derived from a 5-year-old girl’s Burkitt lymphoma tumor in 1973, are a human B cell line. Despite experimental exposure to Epstein-Barr virus (EBV), the established cell line does not exhibit EBV sequences or antigens. These cells showcase round to polymorphic morphology, growing either individually or in large, flat clumps when suspended. With a doubling time of approximately 30-40 hours, subculturing at a density of 0.5-0.7×106 cells/ml is recommended every 2-3 days, employing a split ratio of 1:2 to 1:5. Importantly, culturing flasks must be maintained horizontally. Widely utilized, BJAB cells offer a valuable resource for investigating Burkitt lymphoma and associated research endeavors.
Why choose BJAB from AcceGen?
BJAB cells from AcceGen are prepared by professional operators under optimal conditions. These cells exhibit a healthy and robust cell state, ensuring their viability and culture performance. When stored and cultured in adherence to the provided instructions, these products demonstrate high cell viability and excellent culture performance. By following the recommended protocols and maintaining appropriate culture conditions, users can expect reliable and consistent results from BJAB cell products.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
FOR RESEARCH USE ONLY
The utilization of BJAB cells in various research applications is highly valuable. Firstly, studying the proteomics and transcriptomics of BJAB cells affected by Epstein-Barr virus (EBV) allows for the identification of significant alterations in protein and gene expression profiles upon viral expression. Secondly, BJAB cells serve as an excellent model for investigating apoptosis, enabling the search for potent inducers and pathways of programmed cell death in lymphoma. Such studies contribute to the development of targeted therapies and the discovery of novel anti-cancer agents. Lastly, BJAB cells provide a crucial resource for understanding the process of malignant transformation. By examining the genetic and molecular changes associated with Burkitt lymphoma development and progression, researchers can uncover key mutations, altered signaling pathways, and oncogenic factors. This knowledge enhances our understanding of cancer biology and opens avenues for targeted interventions in lymphomas and other cancers.
